On January 12, 2020 Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leading off-the-shelf, allogeneic T-cell immunotherapy company developing novel treatments for patients with cancer, autoimmune and viral diseases, reported President and Chief Executive Officer Pascal Touchon will share details of the company’s mission, scientific platform and development pipeline during a presentation at the 38th Annual J.P. Morgan Healthcare Conference on Thursday, January 16 at 8:30 a.m. PST at the Westin St. Francis Hotel in San Francisco (Press release, Atara Biotherapeutics, JAN 12, 2020, View Source [SID1234553025]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
"As we enter into this new year, we are proud of our progress building a leading off-the-shelf, allogeneic T-cell immunotherapy company with a robust pipeline," said Pascal Touchon, President and Chief Executive Officer of Atara Biotherapeutics. "Backed by our innovative EBV T-cell platform, next-generation CAR T technologies, state-of-the-art manufacturing capabilities and dedication to developing transformative T-cell immunotherapies for patients, we are confident in our ability to execute on our 2020 plans."
Anticipated key milestones across Atara’s four strategic priorities in 2020 include:
Tab-cel (tabelecleucel)
Submitted clinical trial applications (CTAs) to several European countries in November 2019 to enable opening EU clinical sites in 2020
Begin enrollment in a Phase 2 multi-cohort study including patients with other EBV+ cancers in the second half of 2020
Initiate FDA Biologics License Application (BLA) submission for patients with EBV+ PTLD in the second half of 2020
ATA188
Initiate enrollment of randomized, double-blind, placebo-controlled Phase 1b study in patients with progressive MS in the second or third quarter of 2020
Present six- and twelve-month ATA188 Phase 1a clinical results for cohorts 3 and 4 in the first and second halves of 2020, respectively
ATA2271
Submit next-generation mesothelin-targeted autologous CAR T IND for patients with advanced mesothelioma in the second or third quarter of 2020
EBV CAR T Platform
Academic presentation of an off-the-shelf, allogeneic CD19 CAR T clinical proof-of-principle using a partially HLA matched Epstein-Barr virus T cell academic construct for patients with relapsed/refractory B-cell malignancies at the 2020 Transplantation and Cellular Therapy (TCT) Meetings to be held February 19-23 in Orlando, Fla.
A live audio webcast of the J.P. Morgan Healthcare Conference presentation will be available by visiting the Investors and Media section of the Atara website. An archived replay of the webcast will be available on the Company’s website for 14 days following the live presentation.